Latest AusBiotech journal features special investment edition

Without doubt, capital is the ‘life blood’ of Australia’s promising biotechnology sector, which is needed to go hand-in-hand with the flow of innovative technologies that offer solutions and treatments for our future. This need, and the challenge of securing capital, has prompted this edition’s focus on investment in the life sciences.

In this edition, we ask local and international experts for their views on investment trends and what strategies they are employing in the current economic environment. We ask which companies the experts are watching and why, revealing an impressive array of Australian innovation. We also take a look at recent IPOs and what the next year night hold in IPO and capital raising activity.

As an industry of the future, requiring long-term investment and patient investors, no discussion on investment would be complete without looking at what public policy could do to support the biotechnology sector’s growth, which will provide returns back to the Australian community with economic growth and bio-technological advancement.

The attraction of capital to match the biotechnology with ‘real’ market potential is also one of the sector’s greatest challenges. The need for long-term investment in biotechnology is somewhat at odds with investors’ need for shorter-term investment horizons, so one of the many challenges for biotech companies is to consider how to orient their development to provide an attractive offering.

The journal is complimentary for members of AusBiotech and also has regular features, such as the AusBioSTOCK, an exclusive report from Baillieu Stockbroking’s Joanna Hill.

The link to Australasian Biotechnology has been emailed to all members. If for any reason you did not receive your link, please contact the Editor Lorraine Chiroiu on 03 9828 1414 or email.